Lipella Pharmaceuticals (LIPO) Proxy Filing summary

Executive summary

• Special Meeting scheduled for December 6, 2024, to vote on issuing 20% or more of outstanding common stock via a new equity line of credit (ELOC).

• The ELOC is intended to help regain compliance with Nasdaq’s minimum stockholders’ equity requirement and support business strategy and capitalization.

• Board unanimously recommends voting in favor of the proposal to enable flexibility in capital raising.

• Only stockholders of record as of October 28, 2024, are eligible to vote.

Voting matters and shareholder proposals

• Main proposal is to approve, for Nasdaq Rule 5635(d), the issuance of 20% or more of outstanding shares under the ELOC.

• Approval removes the Exchange Cap, allowing issuance above 19.99% of outstanding shares.

• If not approved, company may face delisting risk and limited capital access.

• Board recommends a “FOR” vote; abstentions and broker non-votes do not affect the outcome.

Board of directors and corporate governance

• Dr. Jonathan Kaufman, President, CEO, and Chairman, is named as proxy and will vote as directed by stockholders.

• Quorum for the meeting is one-third of outstanding shares; proxies can be revoked before or during the meeting.